Polyclonal Antibody Composition for C. difficile Infection Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Clostridium difficile infections, particularly in patients with Inflammatory Bowel Disease, are inadequate due to high recurrence rates and complications, and there is a need for effective methods to manage asymptomatic carriage and prevent flare-ups of C. difficile in IBD patients.

Innovation Solution

Development of a polyclonal antibody composition derived from eggs of hens immunized with Clostridium difficile toxins A, toxin B, and spores, which are administered orally to target and neutralize virulent antigens, thereby reducing infection and flare-ups in IBD patients.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat C. difficile infection, then bacterial growth is inhibited, but recurrence rates increase and treatment efficacy is limited

Engineering Contradiction:

Improvetreatment efficacyVSAvoidrecurrence rate

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent uses antibodies (immunological response) to counteract the harmful effects of C. difficile toxins, converting the body's immune mechanism into a therapeutic benefit that neutralizes toxins without the harmful side effects of antibiotics

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces polyclonal antibodies as an intermediary substance that mediates between the harmful toxins and the patient's body, binding to and neutralizing toxins A and B without disrupting the broader microbiome as antibiotics do

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If immunosuppressive agents are used to treat IBD, then inflammation is reduced, but susceptibility to C. difficile infection increases

Engineering Contradiction:

ImproveinflammationVSAvoidinfection susceptibility

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent uses polyclonal antibodies as an intermediary that provides protective immunity against C. difficile without suppressing the overall immune system, thus reducing infection susceptibility while maintaining the body's ability to fight inflammation

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts and neutralizes specifically the harmful C. difficile toxins from the system using antibodies, rather than broadly suppressing the immune system's response to all pathogens and inflammatory stimuli

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If oral antibiotics are administered, then C. difficile bacteria are targeted, but colonic flora disruption worsens

Engineering Contradiction:

Improveinfection treatmentVSAvoidmicrobiome disruption

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful disruption of microbiome into a benefit by using a biological agent (antibodies) that specifically targets toxins without affecting beneficial bacteria, thus treating infection while preserving microbiome integrity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces polyclonal antibodies as an intermediary that selectively neutralizes C. difficile toxins without interacting with or disrupting the broader colonic flora, providing precise pathogen-specific treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibody composition effectively neutralizes C. difficile toxins and spores, reducing symptoms and recurrence of infections, and can be administered without the need for corticosteroids or other immunosuppressive agents, providing a safe and effective treatment for IBD patients.

Implementation Method 1

polyclonal antibodies against Clostridium difficile... targeting and neutralize virulent antigens

Methodology Applied

Scientific EffectAntibody binding:

Implementation Method 2

comprising antibodies which bind to and neutralize toxins A and B of Clostridium difficile and which agglutinate Clostridium difficile spores

Methodology Applied

Scientific EffectAntibody-mediated agglutination:

Data Source

PatentUS10513552B2Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease

Publication Date: 2019.12.24 IMMUNIMED

AI summary

The present invention provides a polyclonal antibody composition prepared from eggs of hens immunized with virulent antigens of Clostridium difficile for use in the treatment and prevention of C. difficile infections in subjects with Inflammatory Bowel Disease including Ulcerative colitis and Crohn's disease. Respective groups of hens are immunized with Toxin A or Toxin B of Clostridium difficile or a Clostridium difficile spore preparation. The polyclonal antibodies are recovered from eggs pooled from the immunized hens and the resulting antibody-egg powder is administered orally in a therapeutically effective amount to individuals infected with or suspected of being infected with C. difficile.